![James Pan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
James Pan
Founder at Exacis Biotherapeutics, Inc.
James Pan active positions
Companies | Position | Start | End |
---|---|---|---|
Exacis Biotherapeutics, Inc.
![]() Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Founder | 31/12/2019 | - |
Corporate Officer/Principal | 31/12/2019 | - | |
China Immunotech (Beijing) Biotechnology Co., Ltd.
![]() China Immunotech (Beijing) Biotechnology Co., Ltd. BiotechnologyHealth Technology China Immunotech (Beijing) Biotechnology Co., Ltd. is a biotechnology company based in Beijing, China. The company's description is written in a mix of Chinese and English, making it difficult to understand. The company was founded in 2018 by Xue Qiang Zhao, Hong Li Zheng, Wei Rui, and Wei Rui has been the CEO since 2018. | Director/Board Member | - | - |
Chief Executive Officer | - | - |
Career history of James Pan
Training of James Pan
University of Toronto | Doctorate Degree |
Statistics
International
Canada | 2 |
China | 2 |
United States | 2 |
Operational
Founder | 1 |
Corporate Officer/Principal | 1 |
Director/Board Member | 1 |
Sectoral
Consumer Services | 2 |
Health Technology | 2 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
China Immunotech (Beijing) Biotechnology Co., Ltd.
![]() China Immunotech (Beijing) Biotechnology Co., Ltd. BiotechnologyHealth Technology China Immunotech (Beijing) Biotechnology Co., Ltd. is a biotechnology company based in Beijing, China. The company's description is written in a mix of Chinese and English, making it difficult to understand. The company was founded in 2018 by Xue Qiang Zhao, Hong Li Zheng, Wei Rui, and Wei Rui has been the CEO since 2018. | Health Technology |
Exacis Biotherapeutics, Inc.
![]() Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Health Services |
- Stock Market
- Insiders
- James Pan
- Experience